611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Cancer
Resources
Basic InformationLatest News
Weight-Loss Surgery May Curb Risk for Certain CancersCould 'AI' Become a Partner in Breast Cancer Care?Breast Cancer More Lethal for Blacks Than WhitesIncrease in Rate of Breast Reconstruction for MastectomyWith Skin Cancer Surgery, Insurance MattersU.S. Filipinos Have Higher Thyroid Cancer MortalityNeed Cancer Screening? Where You Work MattersMore Women Choose Breast Reconstruction After MastectomyGenetic Variant Tied to Prostate Cancer OutcomesPrimary, Pulmonary Providers Endorse Lung CA ScreeningHow to Talk to Someone With CancerHealth Tip: Food Safety for People With CancerBreast Cancer Screenings Still Best for Early DetectionNew Tool IDs Mortality Risk After Bladder Cancer SurgeryStart Skin Cancer Prevention Early, Health Experts SayNegative Margins, Lymph Node Yields Predict SurvivalDouble Mastectomy May Mean a Hit to the PaycheckMost Cancer Drugs Approved in Europe Show No Survival BenefitLiver Cancer Remains a Major Public Health Burden GloballyInsurance Type Linked to Surgery Delay in MelanomaProvider Advice Impacts Breast Cancer Prevention DecisionsNewer Drug May Prolong Lymphoma RemissionSmoking Cessation Support Less Likely for Cancer PatientsHow Breast Cancer Gene Mutations Raise Risk of TumorsHealth Tip: Screening for Lung CancerOverall Breast Cancer Incidence Up for Some in 2005-2014Obesity Linked to 13 Types of CancerBreast Cancer's Decline May Have Saved 322,000 LivesLegal Cannabis Use Common Among Cancer PatientsUpper Abdominal Cancer Resections Up in OctogenariansVerzenio Approved for Advanced Breast CancerCheckpoint Inhibitors No Less Safe With RadiationAccurate Lung Cancer Staging Depends on Quality Nodal ExamHealth Tip: Recognizing Prostate CancerPropranolol Use Inversely Linked to Melanoma RecurrenceASTRO: SBRT Prolongs Survival in Non-Small-Cell Lung CancerASTRO: Patient Experience of Radiation Better Than ExpectedCentral Neck Dissection Underused in Some Thyroid CAAdding Drug to Standard Care May Prolong Lymphoma SurvivalCancer Risk Up for RA Patients With Venous ThromboembolismFewer Uninsured Cancer Patients After Medicaid ExpansionRadiation and Chemotherapy Together Boost Lung Cancer SurvivalAdjuvant Chemo Beneficial in Advanced Gastroesophageal CATILs Prognostic in Black Triple-Negative Breast Cancer PatientsBlacks, Elderly Missing From U.S. Cancer Clinical TrialsTibetan Yoga Improves Sleep Quality During ChemoCancer Distress May Lead to Missed AppointmentsBreast Cancer Radiation 'Less Scary' Than ThoughtMastectomy Study Confirms 'Jolie Effect'Where It's Legal, One-Quarter of Cancer Patients Use Medical Pot
LinksBook ReviewsSelf-Help Groups
Related Topics

Medical Disorders
Pain Management

Multigene Panel Tests Can ID Hereditary Kidney Cancer


HealthDay News
Updated: Aug 11th 2017

new article illustration

FRIDAY, Aug. 11, 2017 (HealthDay News) -- For patients who lack distinguishing clinical characteristics of known hereditary kidney cancer syndromes, panel testing may be useful for identifying hereditary cancer, according to a study published online Aug. 8 in Cancer.

Kevin A. Nguyen, from the Yale School of Medicine in New Haven, Conn., and colleagues retrospectively reviewed test results and clinical data from 1,235 patients who underwent targeted multigene panel testing of up to 19 genes associated with hereditary kidney cancer. The authors assessed the frequency of positive, inconclusive, and negative results.

The median age at diagnosis was 46 years, which was significantly younger than that of the U.S. population of individuals with kidney cancer. The researchers found that 6.1, 75.5, and 18.4 percent of participants had positive, negative, and inconclusive results, respectively. Folliculin and fumarate hydratase were the most commonly altered genes (altered in 1.8 and 1.3 percent of patients, respectively). The highest rates of variants of unknown significance were in Tuberous Sclerosis Complex 2, mesenchymal epithelial transition factor proto-oncogene, and PMS1 homolog 2, seen in 2.7, 2.2, and 1.7 percent of patients, respectively. The only factor that was identified as predictive of a positive test on multivariate logistic regression was early age of onset (odds ratio, 0.975), which may be an identifying characteristic of low-penetrant syndromes.

"Panel tests may be particularly useful for patients who lack distinguishing clinical characteristics of known hereditary kidney cancer syndromes," the authors write. "The current results support the use of early age of onset for genetic counseling and/or testing."

Two authors are employees of Ambry Genetics, which provided the authors with the dataset for the study.

Abstract
Full Text (subscription or payment may be required)